John Pullman

2.8k total citations
24 papers, 1.0k citations indexed

About

John Pullman is a scholar working on Infectious Diseases, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, John Pullman has authored 24 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 7 papers in Epidemiology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in John Pullman's work include Antimicrobial Resistance in Staphylococcus (8 papers), Bacterial Identification and Susceptibility Testing (5 papers) and Pneumonia and Respiratory Infections (4 papers). John Pullman is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (8 papers), Bacterial Identification and Susceptibility Testing (5 papers) and Pneumonia and Respiratory Infections (4 papers). John Pullman collaborates with scholars based in United States, Spain and Canada. John Pullman's co-authors include Ping Yan, Kristin Taylor, Michael Trautmann, Thomas Blevins, Lisa A. Porter, Christine T. Schulteis, Jaret Malloy, Sue Cammarata, Laura Lawrence and Lawrence S. Phillips and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Diabetes Care and Clinical Infectious Diseases.

In The Last Decade

John Pullman

24 papers receiving 975 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Pullman United States	13	441	306	248	232	228	24	1.0k
Ismail Mitha Denmark	10	997 2.3×	139 0.5×	589 2.4×	230 1.0×	388 1.7×	12	1.4k
J Aubertin France	18	228 0.5×	104 0.3×	188 0.8×	231 1.0×	62 0.3×	92	972
Robert Sauermann Austria	19	44 0.1×	283 0.9×	128 0.5×	255 1.1×	464 2.0×	43	1.1k
Anna K. Poon United States	11	83 0.2×	216 0.7×	110 0.4×	109 0.5×	26 0.1×	21	770
Francesca Crea Italy	13	108 0.2×	220 0.7×	88 0.4×	213 0.9×	16 0.1×	21	612
Pablo Vidal Spain	13	78 0.2×	78 0.3×	84 0.3×	152 0.7×	40 0.2×	55	622
Saroj Khatiwada Nepal	16	211 0.5×	101 0.3×	209 0.8×	133 0.6×	23 0.1×	44	820
Jean-Daniel Baumgartner Switzerland	9	58 0.1×	87 0.3×	135 0.5×	629 2.7×	57 0.3×	13	1.2k
Marise Auxiliadora de Barros Reis Brazil	13	78 0.2×	102 0.3×	121 0.5×	111 0.5×	32 0.1×	31	650
Takashi Inamatsu Japan	17	27 0.1×	336 1.1×	180 0.7×	249 1.1×	67 0.3×	70	962

Countries citing papers authored by John Pullman

Since Specialization

Citations

This map shows the geographic impact of John Pullman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Pullman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Pullman more than expected).

Fields of papers citing papers by John Pullman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Pullman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Pullman. The network helps show where John Pullman may publish in the future.

Co-authorship network of co-authors of John Pullman

This figure shows the co-authorship network connecting the top 25 collaborators of John Pullman. A scholar is included among the top collaborators of John Pullman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Pullman. John Pullman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cornely, Oliver A., George R. Thompson, Àlex Soriano, et al.. (2024). P29 Treatment outcomes with rezafungin and caspofungin in people aged 65 years and above with candidaemia and/or invasive candidiasis: integrated analysis of pooled Phase 2 and Phase 3 data. JAC-Antimicrobial Resistance. 6(Supplement_1). 1 indexed citations

Honoré, Patrick M., Matteo Bassetti, Oliver A. Cornely, et al.. (2024). Length of hospital and intensive care unit stay in patients with invasive candidiasis and/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials. Critical Care. 28(1). 361–361. 5 indexed citations

Nilsson, Anna, John Pullman, Piotr Napora, et al.. (2023). A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection. Clinical Microbiology and Infection. 29(10). 1320–1327. 9 indexed citations

Soriano, Àlex, George R. Thompson, Oliver A. Cornely, et al.. (2023). P22 Patient-level meta-analysis of efficacy and safety from STRIVE and ReSTORE: randomized, double-blinded, multicentre Phase 2 and Phase 3 trials of rezafungin in the treatment of candidaemia and/or invasive candidiasis. JAC-Antimicrobial Resistance. 5(Supplement_1). 2 indexed citations

Cohen, Stuart H., Thomas Louie, Matthew Sims, et al.. (2021). 634. Investigational Microbiome Therapeutic SER-109 Reduces Recurrence of Clostridioides difficile Infection (CDI) Compared to Placebo, Regardless of Risk Factors for Recurrence. Open Forum Infectious Diseases. 8(Supplement_1). S420–S420. 1 indexed citations

Gerding, Dale N., Oliver A. Cornely, Simon Grill, et al.. (2019). Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. The Lancet Infectious Diseases. 19(3). 265–274. 47 indexed citations

Madej, Andrzej, John Pullman, Monica Popescu, et al.. (2019). 2234. Outcomes by Age and Gender from a Global Phase 3 Study of Delafloxacin (DLX) in Community-Acquired Bacterial Pneumonia (CABP). Open Forum Infectious Diseases. 6(Supplement_2). S763–S763. 2 indexed citations

Ford, Christopher B., Barbara McGovern, Darrell S. Pardi, et al.. (2019). 1503. Engraftment of Investigational Microbiome Drug, SER-262, in Subjects Receiving Vancomycin Is Associated with Reduced Rates of Recurrence after Primary Clostridium Difficile Infection (CDI). Open Forum Infectious Diseases. 6(Supplement_2). S547–S548. 9 indexed citations

Ménétrey, Annick, John Pullman, J. Scott Overcash, et al.. (2018). Bone and Joint Tissue Penetration of the Staphylococcus -Selective Antibiotic Afabicin in Patients Undergoing Elective Hip Replacement Surgery. Antimicrobial Agents and Chemotherapy. 63(3). 22 indexed citations

10.

Mehra, Purvi, et al.. (2015). A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. Journal of Antimicrobial Chemotherapy. 71(3). 821–829. 66 indexed citations

11.

Cammarata, Sue, et al.. (2015). Results of a Global Phase 3 Study of Delafloxacin (DLX) Compared to Vancomycin With Aztreonam (VAN) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Open Forum Infectious Diseases. 2(suppl_1). 8 indexed citations

12.

Stryjewski, Martín E., Arnold Lentnek, William O’Riordan, et al.. (2014). A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infectious Diseases. 14(1). 289–289. 56 indexed citations

13.

Blevins, Thomas, John Pullman, Jaret Malloy, et al.. (2011). DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 96(5). 1301–1310. 373 indexed citations

14.

Hamilton, S. M., Amy E. Bryant, Karen C. Carroll, et al.. (2007). In Vitro Production of Panton-Valentine Leukocidin among Strains of Methicillin-Resistant Staphylococcus aureus Causing Diverse Infections. Clinical Infectious Diseases. 45(12). 1550–1558. 58 indexed citations

15.

Pullman, John, Tamara Darsow, & Juan P. Frías. (2006). Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes. Vascular Health and Risk Management. 2(3). 203–212. 36 indexed citations

16.

DeFronzo, Ralph A., Richard M. Bergenstal, William T. Cefalu, et al.. (2005). Efficacy of Inhaled Insulin in Patients With Type 2 Diabetes not Controlled With Diet and Exercise. Diabetes Care. 28(8). 1922–1928. 100 indexed citations

17.

Hagberg, Lars, et al.. (2003). Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis. Respiratory Medicine. 97(6). 625–633. 21 indexed citations

18.

Pullman, John, et al.. (2003). EFFICACY AND TOLERABILITY OF ONCE‐DAILY ORAL THERAPY WITH TELITHROMYCIN COMPARED WITH TROVAFLOXACIN FOR THE TREATMENT OF COMMUNITY‐ACQUIRED PNEUMONIA IN ADULTS. International Journal of Clinical Practice. 57(5). 377–384. 42 indexed citations

19.

Maslanka, Susan E., Jordan W. Tappero, Brian D. Plikaytis, et al.. (1998). Age-DependentNeisseria meningitidisSerogroup C Class-Specific Antibody Concentrations and Bactericidal Titers in Sera from Young Children from Montana Immunized with a Licensed Polysaccharide Vaccine. Infection and Immunity. 66(6). 2453–2459. 61 indexed citations

20.

Lamster, Ira B., John Pullman, Romanita Celenti, & John T. Grbic. (1996). The effect of tetracycline fiber therapy on β‐glucuronidase and interleukin‐1β in crevicular fluid. Journal Of Clinical Periodontology. 23(9). 816–822. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact